| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0168 |
| Trial ID | NCT01840566 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Carmustine|Etoposide|Cytarabine|Melphalan|Pegfilgrastim |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma |
| Year | 2013 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 12-117 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||